Total
0
Shares
Regeneus (ASX:RGS) signs MOU with Kyocera for Progenza
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Regeneus (RGS) has signed an agreement with Kyocera Corporation to give it exclusive negotiation rights to Progenza for treating knee osteoarthritis
  • Progenza is the company's leading cell therapy technology for treating osteoarthritis and other musculoskeletal disorders
  • Kyocera is a major Japanese life sciences company which makes dental and medical products such as artificial joints for the knee and hip
  • Kyocera will conduct due diligence for Progenza and then pay Regeneus 100 million Japanese yen
  • The company will have until the end of July to negotiate a commercial licence for Progenza in Japan
  • Regeneus' shares have sky rocketed 30.2 per cent and are trading for 6.9 cents each

Regenerative medicine company Regeneus (RGS) has signed a non-binding memorandum of understanding with Kyocera Corporation.

Kyocera is a major Japanese multinational life sciences company which produces dental and medical products including artificial joints for the knee and hip.

Under the agreement, Kyocera will gain exclusive negotiation rights to Regeneus' cell therapy technology, Progenza, for the treatment of knee osteoarthritis.

Progenza is made from expanded allogeneic mesenchymal stem cells (MSCs) from human adipose tissue (connective tissue) and contains the bioactive secretions of the cells which have shown increased therapeutic benefit.

It reduces inflammation and promotes healing and repair in the damaged or diseased tissue.

Kyocera will conduct due diligence for Progenza which is expected to take no more than 45 days after the delivery of documentation. Once due diligence is completed, Kyocera will pay Regeneus 100,000,000 JPY (approx. A$1.4 million).

It will have until the end of July to negotiate a commercial licence for Progenza in Japan.

"This Memorandum of Understanding with a company of Kyocera’s prominence is an important step in the commercialisation pathway for Progenza OA in Japan," Regeneus CEO and Executive Director Leo Lee said.

Regeneus' shares have sky rocketed 30.2 per cent and are trading for 6.9 cents each at 12:30 pm AEDT.

RGS by the numbers
More From The Market Herald
AnteoTech (ASX:ADO) - CEO, Derek Thomson - The Market Herald

" AnteoTech (ASX:ADO) receives CE Mark approval for COVID-19 test

AnteoTech (ADO) has received Conformitè Europëenne (CE) Mark registration for its rapid test platform and COVID-19 test.
Imugene (ASX:IMU) - CEO, Leslie Chong - The Market Herald

" Imugene (ASX:IMU) presents key findings to leading cancer research association

Imugene (IMU) presented key findings from its HER-Vaxx immunotherapy and CF33 oncolytic virus programs at the American Association for Cancer Research’s annual meeting.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating - The Market Herald

" ResApp Health (ASX:RAP) raises $5.5M

ResApp Health (RAP) has received firm commitments to raise $5.5 million through a placement.
Opyl (ASX:OPL) - CEO, Michelle Gallaher - The Market Herald - The Market Herald

" Opyl (ASX:OPL) buys back unmarketable shares

Medical tech support provider Opyl (OPL) has completed an off-market share buy-back facility for eligible shareholders who held unmarketable parcels in the company